Financial Data and Key Metrics Changes - Q1 revenue reached $616 million, representing a 25% year-over-year increase [45] - Adjusted EBITDA for the quarter was $208 million, reflecting a 34% margin [45] - Adjusted net income was $165 million, or $0.33 per fully diluted share [49] - Free cash flow was $230 million in Q1 [49] Business Line Data and Key Metrics Changes - CTV (Connected TV) remains the largest and fastest-growing advertising channel, representing a high 40s percentage share of the business [46] - Mobile accounted for a mid-30s percentage share of spend, while display represented a low double-digit share and audio around 5% [46] - The adoption of the Kokai platform accelerated, with about two-thirds of clients now using it, ahead of schedule [60] Market Data and Key Metrics Changes - North America represented approximately 88% of spend, while international markets accounted for about 12% [46] - International growth outpaced North America for the ninth consecutive quarter, driven by CTV [47] Company Strategy and Development Direction - The company aims to capture market share in a more competitive landscape, particularly in the open Internet space [19][40] - Innovations like OpenPath and the acquisition of Sincerra are expected to enhance supply chain efficiency and transparency [24][28] - The focus remains on maintaining independence and objectivity to differentiate from competitors like Google and Amazon [45][82] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to navigate macroeconomic uncertainties and continue to grow [51] - The outlook for Q2 anticipates revenue of at least $682 million, reflecting a 17% year-over-year growth [51] - The company is optimistic about the open Internet's prospects following recent antitrust rulings against Google [19][70] Other Important Information - The company has no debt and ended the quarter with approximately $1.7 billion in cash and short-term investments [49] - A significant share repurchase program was executed, with $386 million of Class A common stock repurchased [50] Q&A Session Summary Question: Can you elaborate on the progress from product and go-to-market changes? - Management highlighted strong Q1 performance and noted that upgrades contributed to outperformance, with Kokai adoption ahead of schedule [56][60] Question: What are the implications of Google's antitrust verdict for DSPs? - Management believes the verdict will create a fairer market, allowing the company to compete more effectively against reduced competition from Google [65][70] Question: How does the company view Q2 guidance amid uncertainty? - Management remains optimistic, citing strong underlying business fundamentals and the ability to assist clients in navigating challenges [72][75] Question: How is the competitive landscape evolving, particularly with Amazon? - Management views Amazon's focus on Prime Video as a limitation, asserting that the company’s CTV growth is outpacing Amazon's advertising growth [80][82] Question: What progress is being made with OpenPath and expectations for the upfront? - Management anticipates a stronger performance for programmatic advertising during the upfronts, with ongoing improvements in OpenPath [90][92]

Eastman Kodak Company (KODK) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Eastman Kodak Quarter One Earnings Conference Call. At this time, all participants are in a listen only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Anthony Redding. Anthony, you may now begin. Speaker1 Thank you, and good afternoon, everyone. I am Anthony Redding, Eastman K ...

Entravision Communications (EVC) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Greetings, and welcome to the Intravision First Quarter twenty twenty five Earnings Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Roynier. Please go ahead. Speaker1 Good afternoon everyone and welcome to Entravision's first quarter twenty twenty five earnings call. I am Roy Near, Vice President of Financial Reporting and Investor Relations. Joining me to ...

StoneCo (STNE) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good evening, Thank you for standing by. Welcome to StoneCo's First Quarter twenty twenty five Earnings Conference Call. By now, everyone should have access to our earnings release. The company also posted a presentation to go along with its call. All material can be found online at investors.stone.co. Throughout this conference call, the company will present certain non IFRS financial information, including adjusted net income, adjusted ...

Toast (TOST) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good afternoon. My name is Tamika, and I will be your conference operator today. At this time, I would like to welcome everyone to the Toast First Quarter twenty twenty five Earnings Conference Call. Today's call will be forty five minutes. I will now turn the call over to Michael Sinnell, Senior Vice President of Finance. You may begin your conference. Speaker1 Thank you, Tamika, and welcome everybody to Toast's earnings conference call f ...

The Joint Corp (JYNT) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Please note this event is being recorded. I would now like to turn the conference over to David Barnard of Alliance Advisors Investor Relations. Please go ahead. Speaker1 Thank you, Drew. Good afternoon, everyone. Again, this is David Barnard with Alliance Advisors Investor Relations. Joining us on the call today are President and CEO, Sanjeev Rasdan and CFO, Jake Singleton. Please note we are using a slide presentation that can b ...

RingCentral (RNG) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Speaker0 Good day, and welcome to the RingCentral First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please also note, today's event is being recorded. I would now like to turn the conference over to Vaibhav Agarwal, Deputy CFO for RingCentral. Please go ahead. Speaker1 Thank you. Good afternoon, and welcome to RingC ...

Financial Data and Key Metrics Changes - The company reported revenue of approximately $4 million for Q1 2025, a decrease from $10 million in the same quarter of 2024, primarily due to a shift in focus towards internal and co-development programs [22][23] - The net loss for the quarter was roughly $46 million, compared to a loss of around $41 million in Q1 2024, resulting in a loss of CAD0.15 per share [24][25] - The company ended the quarter with approximately $630 million in cash and equivalents, along with $180 million in available committed government funding, totaling about $810 million in liquidity [21][27] Business Line Data and Key Metrics Changes - The company maintained a cumulative total of 16 molecules that have reached the clinic, with no new molecules advancing in the quarter [22] - The company initiated work on one partner-initiated program, bringing the cumulative total to 97 programs with downstream participation [21] Market Data and Key Metrics Changes - The market opportunity for ABCL635, targeting vasomotor symptoms associated with menopause, is estimated to exceed $2 billion in annual sales, with approximately 30% of women experiencing moderate to severe symptoms [9][10] Company Strategy and Development Direction - The company is focused on advancing its lead programs, ABCL635 and ABCL575, into clinical trials, with plans to complete the CTA process for both programs [18][19] - The company aims to transition from a platform company to a clinical-stage biotech, with over 20 internal and co-development programs in the pipeline [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the biology and differentiation of ABCL635, highlighting the unmet medical need for non-hormonal treatments for vasomotor symptoms [18] - The company plans to start Phase I studies for ABCL635 in Q3 2025, with key readouts expected in mid-2026 [18] Other Important Information - The company is investing in building clinical manufacturing capabilities, expected to be operational by the end of 2025 [27] - The company has received commitments for funding from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia, which will support its GMP facility and internal pipeline advancement [27] Q&A Session Summary Question: What do you expect this asset needs to see in terms of Phase one data to capture a competitive edge? - Management indicated that they will look for safety data and important biomarker data, which will provide early signs of target engagement and efficacy [30][31] Question: What should we expect to see from the upcoming ABCL575 preclinical data? - Management stated that the preclinical data will include early animal work and PK analysis, with expectations for a superior dosing regimen [35] Question: Given the risk around translatability of NKTR engagement, is there a precedent that gives confidence? - Management noted preclinical data from nonhuman primates provides optimism, but emphasized caution in drug development [37][38] Question: How are you thinking about the next development candidates? - Management is looking for high conviction biology with large unmet medical needs and compelling differentiation, likely focusing on GPCR or ion channel targets [40][41] Question: Can you provide context on the pause of Novorok molecules in the clinic? - Management believes the pause is related to fundraising efforts by Novorok, which is common in the current environment [57] Question: Is there consideration for U.S.-based manufacturing redundancies? - Management confirmed that their current manufacturing facility in Canada supports their clinical trials, and they have not yet considered U.S.-based manufacturing [58][59]

Financial Data and Key Metrics Changes - Net sales for Q1 2025 were $103.6 million, an increase of 8.4% from $95.6 million in the prior year quarter [10] - Sales volume grew by 10.9% year over year, while pricing was unfavorable by $3.9 million [10] - Gross profit increased by 8.4% to $40.8 million, with a consistent gross margin of 39.3% [12][13] - Operating income for Q1 2025 was $7.8 million, down from $8.1 million in the prior year quarter [14] - Net income rose by 5.2% to $6.8 million, with a net income margin of 6.6% [14] - Adjusted EBITDA for Q1 2025 was $11.9 million, compared to $13.5 million in the prior year quarter, with an adjusted EBITDA margin of 11.5% [14][15] Business Line Data and Key Metrics Changes - Sales to chain accounts and distributors increased by 7.1%, while online sales rose by 19.6% [11] - Retail channel sales decreased by 3.2% [12] - The company is combining net sales to chain accounts and distributors into a single category for reporting purposes [11] Market Data and Key Metrics Changes - Strongest growth came from Texas and the Midwest, with California, the largest market, also showing improvement [7] - Online business experienced nearly a 20% sales increase during the first quarter [7] Company Strategy and Development Direction - The company is focused on reducing imports from China, aiming to lower it to under 10% by the end of Q2 2025 [6] - Price increases were implemented on April 1, with additional increases expected in mid-May [7][24] - A new distribution center is expected to enhance capacity and support anticipated growth [9] - The company is committed to balancing shareholder returns with long-term growth investments [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply chain challenges and an uncertain trade environment [6] - The company anticipates net sales for Q2 2025 to increase by high single digits to low double digits compared to the prior year quarter [17] - Gross margin for Q2 2025 is expected to be in line with Q1, with adjusted EBITDA margin projected in the mid-teens [17] Other Important Information - The Board of Directors approved a quarterly dividend of $0.45 per share, payable on May 23, 2025 [16] - As of March 31, 2025, the company had financial liquidity of $46.7 million and $23.8 million in short-term investments [16] Q&A Session Summary Question: What countries are being considered for sourcing to reduce China exposure? - The company plans to move sourcing to Malaysia, Indonesia, Vietnam, and Thailand, aiming for less than 10% exposure to China by August [21][22] Question: How will the company manage the impact of tariffs on pricing? - Price increases have been implemented, ranging from 5% to 20%, depending on the product, with the company absorbing some costs due to high demand [24][25] Question: How are reciprocal tariffs factored into guidance? - The company is currently operating on a day-to-day basis due to the unpredictable nature of tariff changes [26] Question: Is the company in a position to benefit from tariffs compared to competitors? - The company has been proactive in sourcing outside of China, positioning itself to gain market share [28] Question: What is the current status of freight costs? - Freight costs were lower in Q1 compared to Q4, but are expected to rise in Q2 due to ongoing shipping delays [29] Question: What cost-saving initiatives are being implemented? - The company is negotiating with third-party carriers to reduce shipping costs, with initial savings already observed [33][34] Question: What is the expected gross margin trend for the second half of the year? - The company anticipates some compression in gross margins in the second half due to tariffs and duties [40] Question: What is the mix of revenue from domestic manufacturing? - Domestic manufacturing was stable in Q1, but the company is ramping up production due to increased demand [42] Question: What factors are contributing to market share growth? - The company's credibility and reliability during the COVID period have strengthened customer relationships, leading to increased market share [45]

MARA Holdings (MARA) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Robert Samuels - VP - Investor RelationsFred Thiel - Chairman and CEOSalman Khan - CFOStephen Glagola - Director - Equity Research Operator At this time, it is my pleasure to turn the floor over to your host, Robert Samuels, VP of Investor Relations. Sir, the floor is yours. Robert Samuels Thank you, operator. Good afternoon and welcome to Mara's First Quarter twenty twenty five Earnings Call. Thank you for joining us t ...